Univariable analysis evaluating predictors of PFS, OS, NRM and relapse rate of the long-term survivor group
| . | N . | PFS . | P value . | OS . | P value . | NRM . | P value . | Relapse rate . | P value . |
|---|---|---|---|---|---|---|---|---|---|
| 144 . | HR (95% CI) . | HR (95% CI) . | HR (95% CI) . | HR (95% CI) . | |||||
| Age | |||||||||
| <55 y | 95 | 1 | 1 | 1 | 1 | ||||
| ≥55 y | 47 | 3.409 (1.211-9.600) | .02 | 3.312 (1.078-10.180) | .037 | 2.475 (0.769-7.966) | .129 | 7.128 (0.693-73.312) | .099 |
| Sex | |||||||||
| Male | 82 | 1 | 1 | 1 | |||||
| Female | 60 | 0.416 (0.129-1.346) | .143 | 0.551 (0.168-1.812) | .327 | 0.679 (0.204-2.257) | .528 | N/A | |
| Race | |||||||||
| White | 63 | 1 | 1 | 1 | |||||
| Asian | 9 | 0.453 (0.049-4.172) | .489 | 0.707 (0.079-6.333) | .757 | 0.952 (0.073-12.353) | .970 | N/A | |
| Black | 35 | 0.536 (0.317-2.093) | .370 | 0.781 (0.194-3.152) | .729 | 1.130 (0.273-4.674) | .866 | N/A | |
| Hispanic | 32 | 0.607 (0.159-2.314) | .465 | 0.871 (0.217-3.488) | .845 | 1.277 (0.284-5.737) | .750 | N/A | |
| Time from diagnosis to transplant | |||||||||
| <6 mo | 38 | 1 | 1 | 1 | |||||
| 6-12 mo | 37 | 0.922 (0.620-1.371) | .689 | 0.927 (0.615-1.396) | .927 | 1.457 (0.239-8.866) | .683 | N/A | |
| >12 mo | 67 | 0.964 (0.693-1.340) | .825 | 0.915 (0.650-1.290) | .915 | 1.439 (0.291-7.122) | .655 | 0.531 (0.079-3.555) | .514 |
| Period of transplant | |||||||||
| Transplant 2009 to 2012 | 29 | 1 | 1 | 1 | 1 | .329 | |||
| Transplant 2013 to 2016 | 69 | 0.653 (0.215-1.982) | .452 | 0.713 (0.212-2.397) | .584 | 0.577 (1.79-1.860) | .357 | 1.001 (0.077-12.933) | |
| Transplant 2017 to 2019 | 44 | 0.587 (0.060-5.767) | .648 | 0.772 (0.073-8.210) | .830 | N/A | 5.163 (0.191-139.261) | ||
| KPS | |||||||||
| 90-100 | 92 | 1 | 1 | 1 | 1 | ||||
| <90 | 39 | 1.749 (0.537-5.696) | .354 | 1.551 (0.409-5.885) | .519 | 1.048 (0.217-5.051) | .953 | 4.021 (0.563-28.718) | .165 |
| DRI | |||||||||
| Low/intermediate | 99 | 1 | 1 | 1 | 1 | ||||
| High/very high | 37 | 2.161 (0.748-6.242) | .155 | 2.097 (0.664-6.626) | .207 | 1.856 (0.547-6.230) | .321 | 2.752 (0.379-19.965) | .317 |
| HCT-CI | |||||||||
| ≤3 | 99 | 1 | 1 | 1 | 1 | ||||
| >3 | 43 | 0.766 (0.240-2.447) | .654 | 1.013 (0.309-3.326) | .983 | 0.794 (0.227-2.780) | .718 | 0.719 (0.073-7.089) | .777 |
| Patient-donor CMV | |||||||||
| Seropositive-seropositive | 77 | 1 | 1 | 1 | 1 | ||||
| Seropositive-seronegative | 40 | 0.952 (0.290-3.128) | .936 | 0.920 (0.253-3.353) | .9 | 0.708 (0.195-2.568) | .6 | 0.914 (0.178-4.692) | .915 |
| Donor Age | |||||||||
| <35 y | 67 | 1 | 1 | 1 | 1 | ||||
| ≥35 y | 75 | 0.795 (0.288-2.199) | .659 | 0.735 (0.246-2.188) | .580 | 0.759 (0.238-2.427) | .129 | 0.868 (0.124-6.065) | .887 |
| Donor/recipient gender | |||||||||
| Male/male | 50 | 1 | 1 | 1 | 1 | ||||
| Female/female | 29 | 0.523 (0.106-2.607) | .431 | 0.863 (0.158-4.715) | .865 | 1.089 (0.180-6.567) | .926 | N/A | N/A |
| Male/female | 31 | 0.409 (0.079-2.108) | .286 | 0.682 (0.123-3.788) | .662 | 0.842 (0.159-4.450) | .840 | N/A | N/A |
| Female/male | 32 | 1.295 (0.392-4.282) | .671 | 2.077 (0.547-7.879) | .283 | 2.097 (0.452-9.723) | .344 | 0.495 (0.049-5.015) | .552 |
| Donor/recipient relationship | |||||||||
| Parent/child | 15 | 1 | 1 | 1 | 1 | ||||
| Sibling/sibling | 62 | 0.919 (0.101-8.294) | .940 | 0.640 (0.066-6.202) | .700 | 0.665 (0.71-6.228) | .721 | N/A | N/A |
| Child/parent | 65 | 2.635 (0.335-20.689) | .357 | 2.310 (0.291-18.351) | .428 | 1.745 (0.222-13.681) | .596 | N/A | N/A |
| Anti HLA antibody | |||||||||
| No DSA | 105 | 1 | 1 | 1 | |||||
| Anti HLA class I Ab | 16 | 1.119 (0.245-5.110) | .885 | 1.391 (0.298-6.484) | .674 | 1.744 (0.325-9.348) | 0.516 | N/A | N/A |
| Anti HLA class II Ab | 9 | 0.900 (0.113-7.156) | .920 | 1.165 (0.145-9.373) | .886 | 1.431 (0.393-5.217) | 0.587 | N/A | N/A |
| Anti HLA class I and II Ab | 12 | 0.598 (0.076-4.674) | .624 | 0.791 (0.100-6.280) | .824 | 0.995 (0.114-8.679) | 0.996 | N/A | N/A |
| Acute GVHD grades 2-4 | |||||||||
| No | 90 | 1 | 1 | 1 | 1 | ||||
| Yes | 52 | 1.031 (0.366-2.899) | .954 | 1.006 (0.328-3.080) | .992 | 0.889 (0.269-2.938) | .847 | 1.525 (0.231-10.047) | .661 |
| Chronic GVHD at 2 years | |||||||||
| No | 114 | 1 | 1 | 1 | 1 | ||||
| Yes | 28 | 1.642 (0.523-5.160) | .396 | 1.200 (0.328-4.392) | .782 | 1.646 (0.416-6.516) | .477 | 1.434 (0.148-13.922) | .756 |
| . | N . | PFS . | P value . | OS . | P value . | NRM . | P value . | Relapse rate . | P value . |
|---|---|---|---|---|---|---|---|---|---|
| 144 . | HR (95% CI) . | HR (95% CI) . | HR (95% CI) . | HR (95% CI) . | |||||
| Age | |||||||||
| <55 y | 95 | 1 | 1 | 1 | 1 | ||||
| ≥55 y | 47 | 3.409 (1.211-9.600) | .02 | 3.312 (1.078-10.180) | .037 | 2.475 (0.769-7.966) | .129 | 7.128 (0.693-73.312) | .099 |
| Sex | |||||||||
| Male | 82 | 1 | 1 | 1 | |||||
| Female | 60 | 0.416 (0.129-1.346) | .143 | 0.551 (0.168-1.812) | .327 | 0.679 (0.204-2.257) | .528 | N/A | |
| Race | |||||||||
| White | 63 | 1 | 1 | 1 | |||||
| Asian | 9 | 0.453 (0.049-4.172) | .489 | 0.707 (0.079-6.333) | .757 | 0.952 (0.073-12.353) | .970 | N/A | |
| Black | 35 | 0.536 (0.317-2.093) | .370 | 0.781 (0.194-3.152) | .729 | 1.130 (0.273-4.674) | .866 | N/A | |
| Hispanic | 32 | 0.607 (0.159-2.314) | .465 | 0.871 (0.217-3.488) | .845 | 1.277 (0.284-5.737) | .750 | N/A | |
| Time from diagnosis to transplant | |||||||||
| <6 mo | 38 | 1 | 1 | 1 | |||||
| 6-12 mo | 37 | 0.922 (0.620-1.371) | .689 | 0.927 (0.615-1.396) | .927 | 1.457 (0.239-8.866) | .683 | N/A | |
| >12 mo | 67 | 0.964 (0.693-1.340) | .825 | 0.915 (0.650-1.290) | .915 | 1.439 (0.291-7.122) | .655 | 0.531 (0.079-3.555) | .514 |
| Period of transplant | |||||||||
| Transplant 2009 to 2012 | 29 | 1 | 1 | 1 | 1 | .329 | |||
| Transplant 2013 to 2016 | 69 | 0.653 (0.215-1.982) | .452 | 0.713 (0.212-2.397) | .584 | 0.577 (1.79-1.860) | .357 | 1.001 (0.077-12.933) | |
| Transplant 2017 to 2019 | 44 | 0.587 (0.060-5.767) | .648 | 0.772 (0.073-8.210) | .830 | N/A | 5.163 (0.191-139.261) | ||
| KPS | |||||||||
| 90-100 | 92 | 1 | 1 | 1 | 1 | ||||
| <90 | 39 | 1.749 (0.537-5.696) | .354 | 1.551 (0.409-5.885) | .519 | 1.048 (0.217-5.051) | .953 | 4.021 (0.563-28.718) | .165 |
| DRI | |||||||||
| Low/intermediate | 99 | 1 | 1 | 1 | 1 | ||||
| High/very high | 37 | 2.161 (0.748-6.242) | .155 | 2.097 (0.664-6.626) | .207 | 1.856 (0.547-6.230) | .321 | 2.752 (0.379-19.965) | .317 |
| HCT-CI | |||||||||
| ≤3 | 99 | 1 | 1 | 1 | 1 | ||||
| >3 | 43 | 0.766 (0.240-2.447) | .654 | 1.013 (0.309-3.326) | .983 | 0.794 (0.227-2.780) | .718 | 0.719 (0.073-7.089) | .777 |
| Patient-donor CMV | |||||||||
| Seropositive-seropositive | 77 | 1 | 1 | 1 | 1 | ||||
| Seropositive-seronegative | 40 | 0.952 (0.290-3.128) | .936 | 0.920 (0.253-3.353) | .9 | 0.708 (0.195-2.568) | .6 | 0.914 (0.178-4.692) | .915 |
| Donor Age | |||||||||
| <35 y | 67 | 1 | 1 | 1 | 1 | ||||
| ≥35 y | 75 | 0.795 (0.288-2.199) | .659 | 0.735 (0.246-2.188) | .580 | 0.759 (0.238-2.427) | .129 | 0.868 (0.124-6.065) | .887 |
| Donor/recipient gender | |||||||||
| Male/male | 50 | 1 | 1 | 1 | 1 | ||||
| Female/female | 29 | 0.523 (0.106-2.607) | .431 | 0.863 (0.158-4.715) | .865 | 1.089 (0.180-6.567) | .926 | N/A | N/A |
| Male/female | 31 | 0.409 (0.079-2.108) | .286 | 0.682 (0.123-3.788) | .662 | 0.842 (0.159-4.450) | .840 | N/A | N/A |
| Female/male | 32 | 1.295 (0.392-4.282) | .671 | 2.077 (0.547-7.879) | .283 | 2.097 (0.452-9.723) | .344 | 0.495 (0.049-5.015) | .552 |
| Donor/recipient relationship | |||||||||
| Parent/child | 15 | 1 | 1 | 1 | 1 | ||||
| Sibling/sibling | 62 | 0.919 (0.101-8.294) | .940 | 0.640 (0.066-6.202) | .700 | 0.665 (0.71-6.228) | .721 | N/A | N/A |
| Child/parent | 65 | 2.635 (0.335-20.689) | .357 | 2.310 (0.291-18.351) | .428 | 1.745 (0.222-13.681) | .596 | N/A | N/A |
| Anti HLA antibody | |||||||||
| No DSA | 105 | 1 | 1 | 1 | |||||
| Anti HLA class I Ab | 16 | 1.119 (0.245-5.110) | .885 | 1.391 (0.298-6.484) | .674 | 1.744 (0.325-9.348) | 0.516 | N/A | N/A |
| Anti HLA class II Ab | 9 | 0.900 (0.113-7.156) | .920 | 1.165 (0.145-9.373) | .886 | 1.431 (0.393-5.217) | 0.587 | N/A | N/A |
| Anti HLA class I and II Ab | 12 | 0.598 (0.076-4.674) | .624 | 0.791 (0.100-6.280) | .824 | 0.995 (0.114-8.679) | 0.996 | N/A | N/A |
| Acute GVHD grades 2-4 | |||||||||
| No | 90 | 1 | 1 | 1 | 1 | ||||
| Yes | 52 | 1.031 (0.366-2.899) | .954 | 1.006 (0.328-3.080) | .992 | 0.889 (0.269-2.938) | .847 | 1.525 (0.231-10.047) | .661 |
| Chronic GVHD at 2 years | |||||||||
| No | 114 | 1 | 1 | 1 | 1 | ||||
| Yes | 28 | 1.642 (0.523-5.160) | .396 | 1.200 (0.328-4.392) | .782 | 1.646 (0.416-6.516) | .477 | 1.434 (0.148-13.922) | .756 |
HCT-CI, hematopoietic cell transplantation–specific comorbidity index; HR, hazard ratio; N/A, not applicable.